Cytel Blog on Applying Bayesian Methods to COVID-19 Clinical Trials
A Cytel blog post discusses how Bayesian methods have impacted COVID-19 vaccine clinical trials. Using Bayesian statistics can improve study [...]
Lead Author of PRISMA 2020 Statement Discusses Research and Publication Trends
In a recent discussion with Matt Page, lead author of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) [...]
ICER Publishes Draft Evidence Report on Alzheimer’s Disease Drug
The Institute for Clinical and Economic Review (ICER) published a Draft Evidence Report regarding Biogen’s aducanumab. The drug is designed to treat [...]
Model N and Global Pricing Innovations Partner to Improve Market Access
Model N and Global Pricing Innovations have announced a new partnership designed to improve market access. The companies are leaders [...]
PRMA Consulting Offers Concise Market Access Webinar
PRMA Consulting is offering a free 10-minute webinar on optimizing global and regional market access. The webinar will highlight common [...]
New Report Suggests Payer Profitability During COVID-19 Pandemic
A Kaiser Family Foundation brief points to increased profitability for payers during the COVID-19 pandemic. The research group noted that [...]
ISPOR Seeks Input Regarding Live Events
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is seeking your input regarding in-person events during its Europe 2021 [...]
JAMA Report on Reducing Prescription Drug Prices Using Legislation, Notes 159% List Price Increase in 11 Years
A new report discusses legislation that could reduce skyrocketing drug prices. Attempts at the state level have put forth unsupported [...]
BCG Report on Using RWE in Clinical Trials
A Boston Consulting Group (BCG) report discusses the benefits of real world evidence (RWE) in streamlining the clinical trial pipeline. [...]
Healthcare Communications Survey Seeks Your Input
The fourth yearly Healthcare Communications Workforce Insight Survey is taking responses. The survey was created by Paramount Recruitment along with [...]
New Report Claims Reducing Drug Prices Will Not Impact Innovation, Discusses HTA Solution
Patients for Affordable Drugs released a report on how lowering drug prices would fail to impact innovation. The authors note [...]
HealthVerity Discusses How the COVID-19 Pandemic Accelerated RWD and RWE Trends in Drug Development
The COVID-19 pandemic has hastened industry trends when it comes to using real world data (RWD) and real world evidence [...]
ICER’s Protocol on Unsupported Price Increases Discusses 250 Drugs
The Institute for Clinical and Economic Review (ICER) recently published a protocol detailing how it determines unjustified price increases. The [...]
Upcoming Virtual Discussion on Reducing High Prescription Drug Prices Without Impacting Innovation
Patients for Affordable Drugs will host a virtual session on overcoming high drug prices on May 18th at 7 PM [...]
New Report Offers Global Market Insight and Highlights Critical HEOR RWD Trends
A new report discusses health economics and outcomes research (HEOR) trends expected to impact the global economy for the next [...]
New Study Analyzes List and Net Prices of Diabetes Drugs
A new study considers the prices of three categories of drugs used in diabetes. The authors note an increase in [...]
Xcenda Leader Provides Insight on Biosimilars for Payers and Pharma
Managing Director Allen Lising of Xcenda’s FormularyDecisions shared his thoughts on biosimilars. He notes that when it comes to the [...]
New JMCP Article Discusses Calculating the Price Tag of Gene Therapies
An article published in the Journal of Managed Care & Specialty Pharmacy (JMCP) focuses on the price considerations of new [...]
Insights on Excessive Drug Costs and Using QALYs to Determine Value
Dan Ollendorf of the Center for the Evaluation of Value and Risk in Health at Tufts University Medical Center and [...]
How Can RWD Improve Our Global Response to the Next Pandemic?
Panalgo CEO and Founder Joseph Menzin and Center for the Evaluation of Value and Risk in Health Director Peter Neumann [...]
ICER’s New Whitepaper Features Insight on FDA’s Accelerated Approval Pathway and Proposes Drug Pricing Reform
The Institute for Clinical and Economic Review (ICER) published a whitepaper discussing the Food and Drug Administration’s Accelerated Approval Pathway (AAP). The [...]
Does Hydroxychloroquine Work? New COVID-19 Evidence Accelerator Report Uses RWD to Determine Patient Outcomes
The COVID-19 Evidence Accelerator has published a new report in PLOS One. The manuscript examines how hydroxychloroquine and azithromycin affect [...]
How Will Europe Use RWE in Regulatory Decisions and HTAs?
Aetion’s Senior Director of European Business Development Pierre Engel discusses trends in Europe’s use of real world evidence (RWE). He [...]
Aetion President and Co-Founder Discusses RWE in Recent Coronavirus Study
Aetion Co-Founder and President Jeremy Rassen discusses the use of real world evidence (RWE) in a recent Science paper. Researchers [...]
New Study Examines Cost-Effectiveness, Equity, Caregiver Burden, and Other Value Elements in 20 ICER Reports
A new article, published in the Journal of Managed Care and Specialty Pharmacy, examines 32 value elements, including health equity [...]